SCHEMBL7806243

SCHEMBL7806243

COc1cc(NS(=O)(=O)c2cccc(-c3ccc(F)cc3)c2)ccc1NC(=O)Nc1ccccc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KMT2A Q03164 6/20 0.60
MAPT P10636 6/20 0.60
LMNA P02545 5/20 0.60
MEN1 O00255 5/20 0.60
MAPK1 P28482 3/20 0.60
NPSR1 Q6W5P4 3/20 0.56
SMN1; SMN2 Q16637 3/20 0.56
HTT P42858 1/20 0.56
ALDH1A1 P00352 3/20 0.55
KDM4E B2RXH2 2/20 0.55
HPGD P15428 1/20 0.55
ALOX12 P18054 2/20 0.52
IDH2 P48735 4/20 0.52
ACLY P53396 2/20 0.51
PFKFB3 Q16875 1/20 0.50
TP53 P04637 2/20 0.48
CA12 O43570 1/20 0.48
CA1 P00915 1/20 0.48
CA2 P00918 1/20 0.48
CA9 Q16790 1/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL7803343 0.94 MAPT (0.69) KMT2AMAPTLMNAMEN1MAPK1
SCHEMBL7797547 0.91 KMT2A (0.64) KMT2AMAPTLMNAMEN1MAPK1
SCHEMBL7804642 0.89 KMT2A (0.70) KMT2AMAPTLMNAMEN1MAPK1
SCHEMBL7805558 0.87 IDH2 (0.61) KMT2AMAPTLMNAMEN1MAPK1
SCHEMBL7804129 0.86 PFKFB3 (0.60) KMT2AMAPTLMNAMEN1MAPK1
SCHEMBL7806571 0.84 PLAU (0.57) MAPTLMNASMN1; SMN2HTTALDH1A1
SCHEMBL7805075 0.83 IDH2 (0.54) KMT2AMAPTLMNAMEN1MAPK1
SCHEMBL7797518 0.83 CNR1 (0.56) KMT2AMAPTLMNAMEN1MAPK1
SCHEMBL7798880 0.83 MAPT (0.55) KMT2AMAPTLMNAMEN1MAPK1
SCHEMBL7807185 0.82 CNR1 (0.62) KMT2ALMNAMEN1IDH2PFKFB3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORPORATION (FI) 2012-08-02 US disclosed
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORPORATION (FI) 2012-08-02 US disclosed
WO-2010146236-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES BIOTIE THERAPIES CORP. (FI) 2010-12-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120196884-A1 UREA SUBSTITUTED SULPHONAMIDE DERIVATIVES ITGA1, ITGB1, ITGA2B KMT2A 2144/4885MAPT 2831/4885LMNA 2594/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.